EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From Hepatitis to Encephalitis: Neuroinvasion and Antiviral Development in Rift Valley Fever Virus Infection

Sawrab Roy, Lei Shi iD, Shuhui Liu, Wenjun Ma

Pathogens · 2026

DOI: 10.3390/pathogens15090891 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathogens, 2026. Verfasst von Sawrab Roy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology and Integrative Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, USA. Hauptthemen laut MEDLINE: Rift Valley Fever, Rift Valley fever virus, Antiviral Agents, Hepatitis. Die Arbeit nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH, University of Missouri.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen that causes substantial livestock losses and a range of severe human illnesses, including hemorrhagic disease, hepatitis, retinitis, vision loss, and delayed encephalitis. Despite its public health and One Health importance, no approved RVFV-specific antiviral therapy or licensed human vaccine is available. Therapeutic development is challenged by the progression of RVFV disease from acute viremia and hepatic injury to delayed neurologic and ocular complications, highlighting the need for countermeasures that protect both systemic organs and CNS tissues. This review examines RVFV antiviral development in the context of neuroinvasive disease. We summarize evidence on RVFV neuroinvasion and central nervous system injury, including route-dependent entry, blood–brain barrier interactions, immune responses, neuroinflammation, and neuronal damage. We then evaluate major antiviral strategies by mechanism, treatment timing, tissue exposure, and central nervous system relevance. Finally, we propose that future RVFV therapeutics are assessed not only by survival, viremia, and hepatic viral-load endpoints, but also by blood–brain barrier penetration, brain pharmacokinetics, efficacy in neuroinvasive models, delayed-treatment activity, and protection against encephalitis-associated injury. This framework may help prioritize antivirals that control both acute systemic disease and delayed neurological complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rift Valley FeverRift Valley fever virusAntiviral AgentsHepatitisEncephalitisHumansAnimalsBlood-Brain Barrier

Stichwörter der Autor:innen

Rift Valley fever virusantiviral treatmentblood–brain barrier penetrationcombination therapyneuropathogenesistherapeutic window

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Pathobiology and Integrative Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, USA.
  • Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, MO 65211, USA.
  • NextGen Center for Influenza and Emerging Infectious Diseases, University of Missouri, Columbia, MO 65211, USA.

ORCID-Profile: Lei Shi

Förderung

  • NIAID NIH HHS
  • NIH
  • University of Missouri

Zitieren

APA

Roy, S., Shi, L., Liu, S., & Ma, W. (2026). From Hepatitis to Encephalitis: Neuroinvasion and Antiviral Development in Rift Valley Fever Virus Infection. Pathogens. https://doi.org/10.3390/pathogens15090891

Vancouver

Roy S, Shi L, Liu S, Ma W. From Hepatitis to Encephalitis: Neuroinvasion and Antiviral Development in Rift Valley Fever Virus Infection. Pathogens. 2026. doi:10.3390/pathogens15090891

BibTeX
@article{Roy2026,
  author = {Roy, Sawrab and Shi, Lei and Liu, Shuhui and Ma, Wenjun},
  title = {From Hepatitis to Encephalitis: Neuroinvasion and Antiviral Development in Rift Valley Fever Virus Infection},
  journal = {Pathogens},
  year = {2026},
  doi = {10.3390/pathogens15090891}
}
Kostenlos starten →